XOMA Ltd. (Nasdaq: XOMA) is a biotechnology company focused on the discovery, development and manufacturing of monoclonal antibody-based therapeutics for serious unmet medical needs. XOMA's world-class monoclonal antibody technologies have contributed to the development of marketed biologics with a total of more than $1 billion in annual sales and for which XOMA received substantial royalties.
STRATEGY
 
LATEST NEWS
 
HIGHLIGHTS

XOMA Corporation (Nasdaq: XOMA) is a biotech enterprise capitalizing on its antibody legacy in a new way.

With over 35 years of discovery activity, XOMA currently has more than 20 partnered and fully-funded programs with the potential to drive milestone and royalty payments, along with multiple additional programs ready for out-licensing. XOMA's business strategy is to grow shareholder value by combining the revenue streams derived from this existing portfolio with future newly acquired milestone and royalty revenues while adopting a lean cost infrastructure, to deliver growing cash flow and profits.

 

 

Full corporate presentation (pdf)